Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 1/20 | 0.80 |
| ▸ | NAMPT | P43490 | 5/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8917545 | 1.00 | IKBKB (0.80) | IKBKBNAMPTCYP3A4CYP2D6CYP2C9 | |
| Chs-828 SCHEMBL16312347 | 1.00 | IKBKB (0.80) | IKBKBNAMPTCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8918236 | 1.00 | IKBKB (0.80) | IKBKBNAMPTCYP3A4CYP2D6CYP2C9 | |
| Chs-828 SCHEMBL12083293 | 1.00 | IKBKB (0.80) | IKBKBNAMPTCYP3A4CYP2D6CYP2C9 | |
| Chs-828 SCHEMBL7142976 | 0.99 | IKBKB (0.79) | IKBKBNAMPTCYP3A4CYP2D6CYP2C9 | |
| Chs-828 SCHEMBL7148798 | 0.99 | IKBKB (0.79) | IKBKBNAMPTCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8914914 | 0.92 | IKBKB (0.68) | IKBKBNAMPTCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14234450 | 0.90 | IKBKB (0.66) | IKBKBNAMPTCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8918690 | 0.89 | IKBKB (0.64) | IKBKBNAMPTCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8916902 | 0.89 | IKBKB (0.64) | IKBKBNAMPTCYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 384 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034213-A1 | SYSTEMS AND METHODS FOR TARGETING NAD-BASED PATHWAYS FOR TREATMENT OF CANCER | UNIV HONG KONG (CN) | 2026-02-05 | — | — | US | claimed |
| US-20250302977-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING HUMANIZED ANTIBODIES TARGETING UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTOR ASSOCIATED PROTEIN (UPARAP) | RIGSHOSPITALET (DK) | 2025-10-02 | — | — | US | claimed |
| WO-2025202361-A1 | ANTI-GPC1 ANTIBODIES AND USES THEREOF | ADCENDO APS (DK) | 2025-10-02 | — | — | WO | claimed |
| WO-2025099152-A1 | ANTIBODIES AND MOLECULAR CONJUGATES THEREOF TARGETING UPAR | RIGSHOSPITALET (DK) | 2025-05-15 | — | — | WO | claimed |
| US-20250152531-A1 | INHIBITORS OF AUTOPHAGY AND DCAR-1 AS NOVEL ANTHELMINTIC AGENTS | FLORIDA ATLANTIC UNIVERSITY BOARD OF TRUSTEES | 2025-05-15 | — | — | US | claimed |
| US-12233036-B2 | Inhibitors of autophagy and DCAR-1 as novel anthelmintic agents | FLORIDA ATLANTIC UNIVERSITY BOARD OF TRUSTEES (US) | 2025-02-25 | — | — | US | claimed |
| CN-119499386-A | Combined pharmaceutical composition of antitumor drug | 安徽省立医院(中国科学技术大学附属第一医院) | 2025-02-25 | — | — | CN | claimed |
| CN-119499387-A | Combined medicine composition of platinum chemotherapeutic medicine | 中国人民解放军海军军医大学第三附属医院 | 2025-02-25 | — | — | CN | claimed |
| US-20240165132-A1 | METHODS AND MATERIALS FOR TREATING CANCER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2024-05-23 | — | — | US | claimed |
| EP-4363447-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING HUMANIZED ANTIBODIES TARGETING UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTOR ASSOCIATED PROTEIN (UPARAP) | Rigshospitalet (DK) | 2024-05-08 | — | — | EP | claimed |
| US-20180185382-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CASE WESTERN RESERVE UNIVERSITY | 2018-07-05 | — | — | US | claimed |
| EP-3313819-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Case Western Reserve University (US) | 2018-05-02 | — | — | EP | claimed |
| WO-2016210134-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CASE WESTERN RESERVE UNIVERSITY (US) | 2016-12-29 | — | — | WO | claimed |
| EP-2634173-A1 | POLYMORPH OF N-(6-(4-CHLOROPHENOXY)HEXYL)-N'-CYANO-N''-(4-PYRIDYL)GUANIDINE, AND PREPARATION THEREFOR AND USE THEREOF | Tianjin Hemay Bio-Tech Co., Ltd. (CN) | 2013-09-04 | — | — | EP | claimed |
| US-8211912-B2 | Compositions and methods for effecting NAD+ levels using a nicotinamide phosphoribosyl tranferase inhibitor | GEMIN X PHARMACEUTICALS CANADA (CA) | 2012-07-03 | — | — | US | claimed |
| US-8173677-B2 | Compositions and methods for effecting NAD+ levels using a nicotinamide phosphoribosyl transferase inhibitor | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2012-05-08 | — | — | US | claimed |
| US-20090215823-A1 | COMPOSITIONS AND METHODS FOR EFFECTING NAD+ LEVELS USING A NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE INHIBITOR | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2009-08-27 | — | — | US | claimed |
| US-20090162454-A1 | Compositions and Methods for Effecting NAD+ Levels Using A Nicotinamide Phosphoribosyl Tranferase Inhibitor | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2009-06-25 | — | — | US | claimed |
| WO-2002094265-A1 | A METHOD OF MODULATING NF-$G(K)B ACTIVITY | LEO PHARMA A/S (DK) | 2002-11-28 | — | — | WO | claimed |
| US-5696140-A | FOR TREATMENT OF ASTHMA, ALLERGIES, NERVOUS SYSTEM DISORDERS OR CANCER | LEO PHARMACEUTICAL PRODUCTS LTD. (DK) | 1997-12-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180185382-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | PPP2CA, PPP3CA, PPP4C | IKBKB 702/4885NAMPT 915/4885CYP3A4 4796/4885 |
| US-20090215823-A1 | COMPOSITIONS AND METHODS FOR EFFECTING NAD+ LEVELS USING A NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE INHIBITOR | NAMPT, NQO1, NNT | IKBKB 1182/4885NAMPT 1/4885CYP3A4 3092/4885 |
| US-20260034213-A1 | SYSTEMS AND METHODS FOR TARGETING NAD-BASED PATHWAYS FOR TREATMENT OF CANCER | NAMPT, NADK, CD274 | IKBKB 1085/4885NAMPT 1/4885CYP3A4 3429/4885 |
| US-20090162454-A1 | Compositions and Methods for Effecting NAD+ Levels Using A Nicotinamide Phosphoribosyl Tranferase Inhibitor | NAMPT, NAPRT, NNT | IKBKB 2111/4885NAMPT 1/4885CYP3A4 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.